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EditorialRecent research shows maturity in addressing safety issues associated with
CAM therapies
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MComplementary and alternative medicine (CAM) or inte-
rative medicine (IM) is defined in various ways by many
ifferent groups. The most “official” definitions describe
AM in terms of its relationship with the dominant health
are system (e.g., http://nccam.nih.gov/health/whatiscam)
nd integrative medicine as the evidence-informed
lending of CAM and conventional medicine (e.g.,
ttp://www.imconsortium.org/about/home.html), but patients
ften describe CAM as being natural and safe options for
anaging a wide variety of health conditions [1–3]. Yet as we
ll know, being natural does not necessarily mean something
s safe – some very potent toxins are naturally found in
ushrooms, snake venom and berries. Similarly, if a natural
roduct or CAM therapy is expected to have some effect in
he human body, it is reasonable to expect that an effect may
lso cause unwanted consequences for some cases depending
n the genetic make-up of the patient, the patient’s underlying
ondition, the dose of the product or therapy, other products
nd therapies the patient may be using concurrently and/or
he quality of product or skill of the practitioner. Patients and
ractitioners both need accurate and relevant data regarding
ny risks, just as much as they need data regarding efficacy in
rder to make informed decisions about CAM products and
herapies.
This Special Issue of the Journal focuses on safety issues
elated to CAM products and therapies. While many resources
re focused on exploring what works (or does not work), there
re equally important questions regarding safety, which are often
ess prominent in research. There are a number of reasons for
his. One is that doing research on the risks associated with
 treatment is quite challenging. Although most clinical trials
o collect data on adverse events experienced by patients in
he trial, the sample sizes in effectiveness or efficacy trials are
lmost always too small to be able to identify the majority of
dverse events. Similarly, clinical trials generally include only
 This editorial belongs to the Special Issue: Ensuring and Improving Patients’
afety in Integrative Health Care.
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icenses/by-nc-nd/3.0/).atients who are not taking other medications and have no co-
orbidities. In the real world, patients are often more complex
han those taking part in clinical trials and thus more likely to
ave different kinds of reactions to treatments. So, adverse events
re often identified only when large numbers of patients use
reatments as they normally would in the real world.
Trying to identify and investigate adverse events in patients
aking products and therapies in natural settings has its chal-
enges. In many cases, patients do not associate the natural
roduct or CAM therapy with the adverse effect – sometimes the
elief that the CAM treatment is safe is so strong that it is not even
onsidered [2,3]. Also, most countries around the world rely
n passive surveillance systems in which health care providers
and sometimes patients) are asked to voluntarily report sus-
ected adverse events associated with health care interventions.
n some cases, CAM interventions are not included in national
eporting systems. Moreover adverse effects are under reported
or a variety of reasons including: lack of time, lack of stan-
ardized reporting documentation, sensitivity to criticism and
nwillingness to acknowledge mistakes [3,4]. Even for the CAM
herapies that are in widespread use, serious adverse events are
ard to detect because they are rare. To identify the incidence
f rare adverse events one needs to monitor large numbers of
onsultations, much larger that the numbers in randomized con-
rolled trials in the field. For example to be 95% confident that
he incidence of rare adverse events is less than 1 per 10,000 then,
sing Hanley’s Rule of Threes, one would need find no serious
dverse events after monitoring 30,000 consultations [5]. For
his reason studies that seek to document safety issues need to
e designed appropriately.
This Special issue of the European Journal of Integrative
edicine presents articles that illustrate a range of methods that
ighlight what is currently known about the risks associated with
ome of the more common CAM therapies and provides com-
entary on how to move forward when studying this complexopic in the context of integrated medicine.
White et al. [6] argue that studying the safety of CAM and
ntegrative medicine is similar in many ways to studying the
afety of any health care intervention. However, CAM products
ccess article under the CC BY-NC-ND license (http://creativecommons.org/
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nd therapies present some additional challenges such as the
omplexity of many CAM interventions and the concept of a
healing crisis” found in several CAM systems. They advocate
ctive surveillance studies as one way to move forward, as well
s international collaboration between experts. This article has
een selected as the Editor’s choice (open access) because it suc-
inctly outlines the challenges associated with safety research
or researchers (and policy makers) and provides concrete rec-
mmendations for moving forward.
Active surveillance is shown to be a feasible way to explore
erious adverse events associated with the use of CAM in pedi-
trics in the article by Zorzla et al. [7]. This study highlights the
mportance of communication and trust between clinicians and
heir patients as a key to identifying (and managing) suspected
AM-related adverse events, especially in children.
Pohlman et al. [8] describe the development and validation
f active surveillance data collection tools for use by practition-
rs and patients. Their paper demonstrates the kind of rigorous
ethodological work that should underpin active surveillance to
nsure the data collected are robust and clinically meaningful.
Systematic reviews of clinical studies can highlight areas
here further safety research is warranted and provide some
stimates of the rates of risks. For example, Kim et al.
9] identify that relatively few risks associated with cupping
herapy have been reported in Korean studies. However the
ack of reporting sufficient information about risks or adverse
vents in clinical trials makes this kind of review challeng-
ng.
Kim et al. [10] describe an analysis of reports of adverse
vents among acupuncture patients taking warfarin or anti-
latelet drugs in an Oriental medical hospital. In contrast to the
lausible concerns that have been raised about excessive bleed-
ng in patients on warfarin receiving acupuncture, the authors
how relatively low levels of adverse events, and no cases of
xcessive bleeding. Similarly, Cho et al. [11] describe an analy-
is of interactions between warfarin and herbal medicines in an
riental hospital and concluded that herbal medicines used in
orean medical practice appear to be safe in this population.
Wardle and Adams [12] remind us that although research
ends to focus on direct risks associated with CAM and integra-
ive medicine, indirect and non-health risks require our attention
s well. For example, a delay in seeking effective treatment or
nancial hardship caused by paying large sums of money for
reatments which may or may not be effective, are potential
arms that we should discuss with patients.
da Silva et al. [13] monitored and reported on adverse events
n a, survey 1157 acupuncture patient consultations. Much of
he acupuncture was delivered by physicians currently training
n acupuncture. However, despite the inexperience of these prac-
itioners, the investigators report that the level of risk associated
ith acupuncture was relatively low.
Wardle et al. [14] report on the regulatory and legislative
rotection for consumers as experienced in Australia, which has
ne of the more developed legal and policy frameworks for CAM
f any western country. They discuss the tension between the
rimary concern for the patient and the political and professional
nterests of policy makers and practitioners.tive Medicine 6 (2014) 401–403
As patients have become more aware of their rights and have
ad greater access to medical information, medical disputes as
he result of treatment have increased. The survey by Shin et al.
15] highlights the problems experienced by traditional Korean
octors and suggests that legal guidelines and regulations should
e established for the resolution of medical disputes related
o traditional Korean rather than relying on mutual agreement
etween doctors and patients.
Vohra et al. [16] have addressed the issues of safety related
o spinal manipulation from several perspectives. Using social,
egal, clinical and physiological approaches, their project is a
odel of how an integrated interdisciplinary team can work
ogether to improve safety.
Concerns have been expressed about the potential adverse
ffects of herbal medicines on liver function. A systematic search
arried out in 11 Korean databases of clinical trials in which
atients were treated herbal medicine suggests that the incidence
f liver injury is likely to be small (Lee et al. [17]). The authors
mphasize the need to collect data in a uniform manner across
ractice and research.
The use of qualitative methodology can enhance shared deci-
ion making, particularly when dealing with complex attitudes
o risk. Leach et al. [18] developed a patient information leaflet
or osteopathic practice and used focus groups with patients
nd practitioners to test the leaflet to explore user perceptions.
he authors report that further work is needed to develop a risk
ommunication strategy for use in osteopathic practice.
The range of papers in this Special issue demonstrates how
esearchers are making serious attempts to assess and explore
ays to improve the safety of natural products and CAM ther-
pies. Taking together the range of articles in this issue, it is
ncouraging to see a considerable maturity emerging from the
esearch community. The need for active surveillance is increas-
ngly acknowledged to be essential, and this issue provides
ncouraging evidence that both professional CAM groups and
AM researchers are able to work together in the interest of
atients to address the safety agenda.
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